Portfolio news 0

Strong 2025 performance; full year revenue growth slightly ahead of guidance

• The Group expects to report revenue of approximately £223 - £224 million (FY24: £183.2 million), representing growth of approximately 22% on a reported basis and 24% at constant currency, slightly ahead of the Group's guidance range of 20-23% constant currency growth.
• Continued progress on path to profitability.

Broad-based growth across all geographies, customer end markets and product categories

• Continued commercial momentum with revenue growth increasing by more than 20% constant currency across each region (EMEAI, APAC and AMR).
• Across customer end markets, Clinical revenue grew by approximately 60% on a reported basis, BioPharma by approximately 30% and Applied Industrial by approximately 27%. Research revenue grew by approximately 15% during the period despite end-market funding pressures.1
• Growth was delivered across all product types, led by the PromethION range, which grew by more than 40% year-on-year on a reported basis.

Business remains well capitalised to deliver on its goals

Oxford Nanopore ended the year with approximately £302 million in cash, cash equivalents and other liquid investments as at 31 December 2025 (FY24: £403.8 million), ahead of consensus expectations helped by improving working capital, providing continued balance sheet strength to support execution of the Group's strategy.

Notice of Results

Oxford Nanopore will announce its preliminary annual results for the twelve months ended 31 December 2025 on Monday 2 March 2026. 

Management will host a virtual presentation on the same day at 9:30am GMT / 4:30am EST, followed by a Q&A session accessible via webcast and conference call.

-ENDS-